SG11201811015RA - Antibodies specific for hyperphosphorylated tau and methods of use thereof - Google Patents

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Info

Publication number
SG11201811015RA
SG11201811015RA SG11201811015RA SG11201811015RA SG11201811015RA SG 11201811015R A SG11201811015R A SG 11201811015RA SG 11201811015R A SG11201811015R A SG 11201811015RA SG 11201811015R A SG11201811015R A SG 11201811015RA SG 11201811015R A SG11201811015R A SG 11201811015RA
Authority
SG
Singapore
Prior art keywords
lundbeck
ottiliavej
valby
international
january
Prior art date
Application number
SG11201811015RA
Inventor
Jan Pedersen
Kristian Kjaergaard
Lars Pedersen
Abdur-Rasheed Asuni
Nina Rosenqvist
Justus Daechsel
Karsten Juhl
Lena Tagmose
Mauro Marigo
Thomas Jensen
Søren Christensen
Laurent David
Christiane Volbracht
Lone Helbo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG11201811015RA publication Critical patent/SG11201811015RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Abstract

X 10000 7500 3 5000 2500 I- (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 January 2018 (18.01.2018) W I PO I PCT omit °nolo omm olonmll °nom oimIE (10) International Publication Number WO 2018/011073 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61P 25/28 A61K 39/395 (2006.01) A61K 49/00 G01N 33/68 (2006.01) A61K 39/00 (21) International Application Number: PCT/EP2017/067067 (22) International Filing Date: 07 July 2017 (07.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA201600416 12 July 2016 (12.07.2016) DK PA201700005 04 January 2017 (04.01.2017) DK PA201700008 04 January 2017 (04.01.2017) DK PA201700179 14 March 2017 (14.03.2017) DK (71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, 2500 Valby (DK). (72) Inventors: PEDERSEN, Jan, Torleif; c/o H. Lundbeck A/ S Ottiliavej 9, 2500 Valby (DK). KVERGAARD, Krist- ian; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). PEDERSEN, Lars, Ostergaard; c/o H. Lundbeck A/S Ot- tiliavej 9, 2500 Valby (DK). ASUNI, Abdur-Rasheed; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). ROSEN- QVIST, Nina, Helen; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). DAECHSEL, Justus, Claus, Alfred; c/ o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). JUHL, Karsten; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Val- by (DK). TAGMOSE, Lena; c/o H. Lundbeck A/S Ot- tiliavej 9, 2500 Valby (DK). MARIGO, Mauro; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). JENSEN, Thomas; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Val- by (DK). CHRISTENSEN, Soren; c/o H. Lundbeck A/ S, Ottiliavej 9, Valby, 2500 (DK). DAVID, Laurent; c/ o H. Lundbeck A/S, Ottiliavej 9, by, 2500 (DK). VOL- BRACHT, Christiane; c/o H. Lundbeck A/S, Valby, 2500 (DK). HELBO, Lone; c/o H. Lundbeck A/S, Ottiliavej 9, Valby, 2500 (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (2006.01) (2006.01) (2006.01) (54) Title: ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF Figure 1 nM antibody n C10-2 • C10-2_1432S_ q C10-2_N32S_A101T (57) : The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer s disease and other tauopathies. [Continued on next page] WO 2018/011073 Al MIDEDIMOHNIIMEIHRIglillEillIHMEHOM TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201811015RA 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof SG11201811015RA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201600416 2016-07-12
DKPA201700005 2017-01-04
DKPA201700008 2017-01-04
DKPA201700179 2017-03-14
PCT/EP2017/067067 WO2018011073A1 (en) 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201811015RA true SG11201811015RA (en) 2019-01-30

Family

ID=60941665

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811015RA SG11201811015RA (en) 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Country Status (40)

Country Link
US (5) US10472415B2 (en)
EP (2) EP3484916B1 (en)
JP (2) JP7029415B2 (en)
KR (1) KR102551971B1 (en)
CN (2) CN109618556B (en)
AU (2) AU2017295608B2 (en)
BR (1) BR112018004916A2 (en)
CA (1) CA3027561A1 (en)
CL (1) CL2019000082A1 (en)
CO (1) CO2018014325A2 (en)
CY (1) CY1123995T1 (en)
DK (1) DK3484916T3 (en)
DO (1) DOP2018000281A (en)
EC (1) ECSP19005417A (en)
ES (1) ES2862427T3 (en)
GE (1) GEP20217222B (en)
HR (1) HRP20210522T1 (en)
HU (1) HUE053679T2 (en)
IL (1) IL263530B2 (en)
JO (1) JOP20180117B1 (en)
LT (1) LT3484916T (en)
MA (2) MA56165A (en)
MX (1) MX2019000476A (en)
MY (1) MY197836A (en)
NI (1) NI201900003A (en)
NZ (1) NZ748983A (en)
PE (1) PE20190227A1 (en)
PH (1) PH12018502613A1 (en)
PL (1) PL3484916T3 (en)
PT (1) PT3484916T (en)
RS (1) RS61646B1 (en)
RU (1) RU2760875C1 (en)
SG (1) SG11201811015RA (en)
SI (1) SI3484916T1 (en)
SV (1) SV2019005807A (en)
TN (1) TN2018000419A1 (en)
TW (1) TWI747922B (en)
UA (1) UA124104C2 (en)
WO (1) WO2018011073A1 (en)
ZA (1) ZA201808329B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894994C (en) 2012-12-21 2019-11-12 National Institute Of Radiological Sciences Compounds for imaging tau proteins that accumulate in brain
US10112990B2 (en) 2015-06-05 2018-10-30 Genentech, Inc. Anti-Tau antibodies and methods of use
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
KR102551971B1 (en) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 Antibodies specific for hyperphosphorylated tau and methods for their use
CN117820467A (en) 2016-12-07 2024-04-05 基因泰克公司 anti-TAU antibodies and methods of use
KR20230146126A (en) 2016-12-07 2023-10-18 제넨테크, 인크. Anti-tau antibodies and methods of use
JP7217710B2 (en) * 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット Antibodies specific for hyperphosphorylated tau for the treatment of eye diseases
KR20190134997A (en) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. Anti-TAU Antibodies and Methods of Use thereof
MA50397A (en) 2017-10-16 2020-08-26 Eisai R&D Man Co Ltd ANTI-BODY ANTI-TAU AND THEIR USES
JP2021512602A (en) * 2018-02-01 2021-05-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． A binding molecule that specifically binds to tau
WO2019171259A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
WO2020123492A1 (en) * 2018-12-10 2020-06-18 New York University Monoclonal antibodies targeting c-terminal region of phosphorylated tau
US20220187322A1 (en) 2019-03-28 2022-06-16 H. Lundbeck A/S Use of a ps396 assay to diagnose tauophaties
CN114641490B (en) * 2019-08-06 2023-06-06 新旭生技股份有限公司 Antibodies that bind to pathological TAU species and uses thereof
WO2021097243A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Inc. Compounds for degrading tau protein aggregates and uses thereof
CA3227440A1 (en) 2021-07-27 2023-02-02 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE172879T1 (en) 1989-08-09 1998-11-15 Rhomed Inc DIRECT RADIO LABELING OF ANTIBODIES AND OTHER PROTEINS USING TECHNETIUM OR RHENIUM
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JPH06508880A (en) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト Thermotropic liquid crystal segmented block copolymer
DE69230148T2 (en) 1991-12-06 2000-05-04 Max Planck Gesellschaft Tools for the diagnosis and treatment of Alzheimer's disease.
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
AT500379B8 (en) * 2001-02-02 2009-08-15 Axon Neuroscience TAU PROTEINS
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1940442A4 (en) 2005-08-04 2009-08-19 Einstein Coll Med Phosphorylation of tau by abl
JP5525729B2 (en) 2005-11-28 2014-06-18 ゲンマブ エー／エス Recombinant monovalent antibody and production method thereof
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc Hco32 and hco27 and related examples
US20100239570A1 (en) * 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN106390107B (en) 2009-06-10 2019-12-31 纽约大学 Immune targeting of pathological TAU proteins
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
ES2686550T3 (en) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Human anti-tau antibodies
JP6457263B2 (en) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド Tau protease composition and methods of use
BR122021017560B1 (en) * 2011-10-07 2023-03-07 Katholieke Universiteit Leuven ANTIBODY, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION, USES OF AN ANTIBODY, IN VITRO METHOD, POST-MORTEM DETECTION METHOD OF PHOSPHO-TAU MULTIMERS, IN VITRO METHOD OF DETECTION OF THE FORMATION OF AN IMMUNE COMPLEX, TEST KITS, ISOLATED CELL LINE AND METHOD OF IN VITRO DETECTION OF PHOSPHO-TAU MULTIMERS
JP6293731B2 (en) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． Humanized tau antibody
KR102494798B1 (en) 2012-07-03 2023-02-06 워싱턴 유니버시티 Antibodies to tau
SI2885010T1 (en) 2012-08-16 2020-07-31 Ipierian, Inc. Methods of treating a tauopathy
EA035943B1 (en) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Antibody binding to human tau protein
WO2014170549A1 (en) 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
EP3098242B1 (en) 2014-01-23 2018-08-29 Asahi Kasei Kabushiki Kaisha Block copolymer composition and adhesive composition
EP3166688A4 (en) 2014-07-08 2017-12-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
KR102551971B1 (en) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 Antibodies specific for hyperphosphorylated tau and methods for their use
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7217710B2 (en) 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット Antibodies specific for hyperphosphorylated tau for the treatment of eye diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Also Published As

Publication number Publication date
JP2022023096A (en) 2022-02-07
NZ748983A (en) 2022-12-23
CN109618556B (en) 2022-10-21
IL263530B2 (en) 2023-02-01
IL263530B (en) 2022-10-01
BR112018004916A2 (en) 2018-12-11
ECSP19005417A (en) 2019-01-31
RS61646B1 (en) 2021-04-29
EP3878864A1 (en) 2021-09-15
US10647762B2 (en) 2020-05-12
SI3484916T1 (en) 2021-08-31
AU2017295608A1 (en) 2018-12-20
PH12018502613A1 (en) 2019-09-30
SV2019005807A (en) 2019-02-13
MA45655A (en) 2019-05-22
HRP20210522T1 (en) 2021-05-14
AU2024201450A1 (en) 2024-03-28
JP7029415B2 (en) 2022-03-03
US10487142B2 (en) 2019-11-26
AU2017295608B2 (en) 2024-01-04
EP3484916A1 (en) 2019-05-22
US20190284266A1 (en) 2019-09-19
ES2862427T3 (en) 2021-10-07
TWI747922B (en) 2021-12-01
KR20190028436A (en) 2019-03-18
MY197836A (en) 2023-07-20
RU2760875C1 (en) 2021-12-01
HUE053679T2 (en) 2021-07-28
JOP20180117B1 (en) 2022-03-14
US10472415B2 (en) 2019-11-12
DOP2018000281A (en) 2019-02-15
PE20190227A1 (en) 2019-02-13
DK3484916T3 (en) 2021-04-06
CA3027561A1 (en) 2018-01-18
ZA201808329B (en) 2020-02-26
JP7244600B2 (en) 2023-03-22
WO2018011073A1 (en) 2018-01-18
US20220177557A1 (en) 2022-06-09
MX2019000476A (en) 2019-06-10
CY1123995T1 (en) 2022-05-27
EP3484916B1 (en) 2021-03-03
US20200109192A1 (en) 2020-04-09
JOP20180117A1 (en) 2019-01-30
CN109618556A (en) 2019-04-12
US20190284265A1 (en) 2019-09-19
IL263530A (en) 2019-01-31
CN116041504A (en) 2023-05-02
MA56165A (en) 2022-04-20
TW201809004A (en) 2018-03-16
US11111290B2 (en) 2021-09-07
US20180016330A1 (en) 2018-01-18
CL2019000082A1 (en) 2019-04-05
CO2018014325A2 (en) 2019-01-18
JP2019529336A (en) 2019-10-17
NI201900003A (en) 2020-04-27
TN2018000419A1 (en) 2020-06-15
GEP20217222B (en) 2021-02-10
KR102551971B1 (en) 2023-07-07
PL3484916T3 (en) 2021-07-19
LT3484916T (en) 2021-04-26
MA45655B1 (en) 2021-04-30
PT3484916T (en) 2021-03-31
UA124104C2 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
SG11201811015RA (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201810149VA (en) Anti hla-g specific antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201906264YA (en) Improved serum albumin binders
SG11201906341XA (en) Improved serum albumin binders
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201806190TA (en) Isotachophoresis for purification of nucleic acids
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201908549RA (en) Automated quality control and spectral error correction for sample analysis instruments
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201809716VA (en) T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201901468SA (en) Antibodies with reduced binding to process impurities
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates